[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-cancer":730},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,228,0,25,[9,40,82,106,139,161,191,227,289,315,356,375,399,429,455,480,509,542,570,590,611,630,659,684,708],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100054214",false,"NCT06476067","Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma","Predicting Postoperative Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Patients who had histologically confirmed ESCC.\n2. Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery.\n3. Patients for whom tissue samples are available\n4. Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery.\n5. Written informed consent following full study information is provided to the patient.\n\nExclusion Criteria:\n\n1. Patients lacking clinical information within 2 years of surgery.\n2. Patients with multiple cancers.","ALL","20 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.",[24,25,26],"Esophageal Cancer","Recurrence","DNA Methylation","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2006-01-01",{"date":35,"type":20},"2028-06-18",{"name":37,"class":38},"City of Hope Medical Center","OTHER",2,{"id":41,"slug":4,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-","18 Years",{"count":48,"type":20},104,"INTERVENTIONAL",[51],"NA","This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[54,55,56,57,58,59,60,24,61,62,63,64,65,66,67,68,69,70,71],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Breast Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Gall Bladder Cancer","Gastric Cancer","Kidney Cancer","Liver Cancer","Lung Cancer","Head and Neck Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","Sarcoma","2026-07-01",{"date":74,"type":31},"2026-07-02",{"date":76,"type":31},"2026-02-11",{"date":78,"type":20},"2027-08-31",{"name":80,"class":38},"Alliance for Clinical Trials in Oncology",18,{"id":83,"slug":4,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":46,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":49,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100453329","NCT05183126","Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer","Phase IV Single-arm Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer","Inclusion Criteria:\n\n* Planned paclitaxel 80 mg\u002Fm\\^2, 1-hour infusion\n* Evaluable computed tomography (CT) scan, positron emission tomography computed tomography (PET-CT) scan, or MRI scan (e.g. scan of the chest, abdomen, or pelvis for any indication w\u002Fin 1 year)\n* Female\n* ≥ 18 years old\n* Adequate organ function to receive paclitaxel treatment as defined in the protocol\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Concomitant administration of any moderate or strong inducer or inhibitor of CYP2C8, including rifampin or clopidogrel.\n* History of hypersensitivity reaction to paclitaxel or any components of paclitaxel (e.g., Cremophor EL) that precludes continued treatment with standard dose and infusion length\n* Pregnant or nursing\n* Receiving any other dose (i.e., not 80 mg\u002Fm2) or infusion rate (i.e., not 60 minute infusion) either due to toxicity during a previous cycle or any other reason","FEMALE",{"count":90,"type":20},22,[92],"PHASE4","The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low\u002Fsarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low\u002Fsarcopenic SMA normalizes the levels to those of patients with normal SMA.",[57,95,24],"Metastatic Gastric Cancer",[97],"pharmacokinetics",{"date":74,"type":31},{"date":100,"type":31},"2022-03-28",{"date":102,"type":20},"2026-11",{"name":104,"class":38},"University of Michigan Rogel Cancer Center",1,{"id":107,"slug":4,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":49,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":138},"100626103","NCT07431281","Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced\u002FMetastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)","Inclusion Criteria:\n\n* Capable of giving signed informed consent\n* Participant must be 18 years or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.\n* Previously untreated histologically documented unresectable, locally advanced, or metastatic gastric, GEJ, or distal esophagus (distal third of the esophagus) adenocarcinoma\n* Positive CLDN18.2 expression, as determined prospectively by central IHC testing\n* Confirmed PD-L1 CPS status by central IHC testing and ICI eligibility per investigator judgement is required to determine cohort eligibility as described below:\n\n  1. Cohort 1: PD-L1 positive as determined by central IHC testing and the participant is deemed ICI eligible per investigator judgement.\n  2. Cohort 2: PD-L1 negative as determined by central IHC testing OR the participant is ICI ineligible\n* ECOG performance status of 0 or 1 with no deterioration to \\> 1 over the previous 2 weeks prior to baseline at screening and prior to randomisation.\n* Minimum life expectancy of ≥ 12 weeks.\n* At least one lesion (measurable and\u002For non-measurable) that can be accurately assessed by the investigator based on RECIST 1.1.\n* Adequate organ and bone marrow function as specified in the protocol\n* Body weight ≥ 35 kg.\n* Sex and contraceptive requirements\n\nExclusion Criteria:\n\n* Known HER2-positive status\n* Significant or unstable gastric bleeding and\u002For untreated gastric ulcers.\n* Active or history of autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment or assessed by investigator as not appropriate to participate due to undue risk are excluded.\n* CNS pathology\n* Clinically significant pleural effusions or ascites and\u002For pleural effusions or ascites that require drainage, peritoneal shunt, or indwelling catheter\u002Fdrain.\n* Require parenteral nutrition support due to gastric or gastrointestinal obstruction.\n* Peripheral neuropathy, sensory or motor, ≥ CTCAE Grade 2 at screening.\n* Persistent toxicities caused by previous anticancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.\n* Cardiac abnormalities as outlined in the protocol\n* Uncontrolled diabetes or diabetic neuropathy within 3 months prior to randomisation.\n* Infectious disease including active hepatitis A infection; uncontrolled hepatitis B and\u002For chronic or active hepatitis B with HBV DNA ≥ 100 IU\u002FmL; Known chronic, active, or uncontrolled hepatitis C; HIV infection that is not well controlled\n* Known partial or total DPD enzyme deficiency",{"count":113,"type":20},2130,[115],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.",[62,118,24],"Gastroesophageal Junction Adenocarcinoma",[120,121,122,123,124,125,126,127,128],"Advanced Gastroesophageal Junction (GEJ) Adenocarcinoma,","Advanced Gastric Adenocarcinoma,","Advanced Esophageal Adenocarcinoma,","Metastatic Gastric Adenocarcinoma,","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,","Metastatic Esophageal Adenocarcinoma,","Claudin 18.2,","PD-L1,","Human epidermal growth factor receptor 2 (HER2) Negative","2026-06-30",{"date":72,"type":31},{"date":132,"type":31},"2026-02-03",{"date":134,"type":20},"2031-10-27",{"name":136,"class":137},"AstraZeneca","INDUSTRY",286,{"id":140,"slug":4,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":49,"phases":148,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100621199","NCT07367516","Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","A Phase Ib\u002FII Clinical Trial Evaluating the Safety and Efficacy of TQB6411 Injection in Participant s With Recurrent or Metastatic Esophageal Cancer Who Have Failed Prior PD-1\u002FPD-L1 Inhibitor Plus Platinum-Based Chemotherapy","Inclusion Criteria:\n\n* Participants voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance.\n* Age between 18 and 75 years old (inclusive)\n* Eastern Cooperative Oncology Group (ECOG) score of 0-1\n* Expected survival \\>12 weeks\n* At least one measurable lesion per RECIST v1.1\n* Laboratory criteria(no hematopoietic growth factor correction within 7 days)：\n\n  * Hemoglobin (HGB) ≥90 g\u002FL;\n  * Absolute neutrophil count (NEUT) ≥1.5×10⁹\u002FL;\n  * Platelets (PLT) ≥90×10⁹\u002FL;\n  * Total bilirubin (TBIL) ≤1.5×ULN;\n  * Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×ULN (≤5×ULN if liver metastases present);\n  * Serum creatinine (CR) ≤1.3×ULNorcreatinine clearance rate (CCR) ≥50 mL\u002Fmin;\n* Histologically\u002Fcytologically confirmed recurrent or metastatic Esophageal cancer\n* Failure\u002Fintolerance to prior PD-1\u002FPD-L1 inhibitor plus platinum-based chemotherapy for recurrent\u002Fmetastatic Esophageal Carcinoma (EC)\n* Willingness to provide archived or fresh tumor tissue for biomarker analysis.\n* Females of childbearing potential: Negative serum\u002Furine pregnancy test within 7 days before enrollment and agreement to use effective contraception during and for 6 months post-study. Males: Agreement to use effective contraception during and for 6 months post-study.\n\nExclusion Criteria:\n\n* Current or History of Other Malignancies\n* Participants with any condition that may compromise venous access for drug administration or blood sampling are excluded.\n* Participants with prior treatment-related adverse reactions that have not recovered to ≤ Grade 1 per CTCAE v5.0 criteria.\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose, Scheduled major surgery during the study intervention period, Non-healing wound, ulcer, or bone fracture at screening\n* Participants with any bleeding\u002Fhemorrhagic event ≥ Grade 3 (per CTCAE v5.0) occurring within 4 weeks before the first dose are excluded\n* History of Thromboembolic Events within 6 Months\n* Poorly Controlled Active Viral Hepatitis\n* Participants with active syphilis infection requiring antimicrobial therapy are excluded\n* Participants with any of the following pulmonary conditions are excluded: active tuberculosis, idiopathic pulmonary fibrosis (IPF), organizing pneumonia, drug-induced\u002Fradiation pneumonitis requiring treatment, symptomatic active pneumonia, or history of interstitial lung disease (ILD) requiring therapy\n* History of Substance Abuse or Psychiatric Disorders\n* History of Allogeneic Transplantation (Bone Marrow or Solid Organ)\n* History of Hepatic Encephalopathy\n* Major Cardiovascular Diseases\n* Active or Uncontrolled Severe Infections\n* Renal Failure Requiring Dialysis (Hemodialysis\u002FPeritoneal Dialysis)\n* History of Immunodeficiency\n* Poorly Controlled Autoimmune Disease\n* Poorly Controlled Autoimmune Disease \\& Epilepsy Requiring Treatment\n* Poorly Controlled Diabetes\n* Tumor-Related Symptoms and Treatment Considerations：\n\n  * Exclusion Criterion - Recent Anticancer Treatment (≤3 Weeks or Within 5 Half-Lives)\n  * Recent Use of National Medical Products Administration (NMPA) -Approved Anticancer Traditional Chinese Medicine (≤1 Week Prior to Treatment)\n  * Radiologically Confirmed Tumor Encasement of Major Vessels with High Bleeding Risk\n  * Uncontrolled Effusions Requiring Repeated Drainage\n  * Known to have spinal cord compression, leptomeningeal metastasis\u002Fcarcinomatous meningitis, or symptomatic brain metastases with less than 4 weeks of symptom\u002Fimaging control.\n* Known Hypersensitivity to Investigational Drug or Excipients\n* Prior Treatment with Topoisomerase I Inhibitor-Based ADCs and\u002For Irinotecan Chemotherapy\n* Prior Participation in Anticancer Clinical Trials Within 4 Weeks\n* Investigator-Assessed Safety or Compliance Concerns","75 Years",{"count":147,"type":20},105,[149,150],"PHASE1","PHASE2","The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1\u002FPD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.",[24],{"date":74,"type":31},{"date":155,"type":31},"2026-02-12",{"date":157,"type":20},"2027-03",{"name":159,"class":137},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",30,{"id":162,"slug":4,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":49,"phases":170,"briefSummary":171,"conditions":172,"keywords":175,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":190},"100609678","NCT07217704","Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET\u002FCT for the Detection of Metastatic Disease in Adults With Gastric or Esophageal Cancer","FAPI-GO","Inclusion Criteria:\n\n* Male and female adults ≥ 18 years.\n* Participants with confirmed gastric, esophageal or gastroesophageal malignancy undergoing staging evaluation for treatment planning.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Provided signed, written informed consent prior to any study-related procedures.\n* Participants are required to have a ceCT scan of chest, abdomen and pelvis as per standard clinical practice and practice guidelines either 21 days or less prior to entry or planned within 21 days of \\[¹⁸F\\]FAPI-74 administration.\n* For women who are not postmenopausal (two years of amenorrhea) or surgically sterile (absence of ovaries and\u002For uterus): agreement to use medically accepted, highly effective methods of contraception (e.g., hormonal implants, combined oral contraceptives, vasectomized partner, during the trial intervention period.\n\nExclusion Criteria:\n\n* Unequivocal evidence of metastases at the time of enrollment that would preclude surgery as a treatment option.\n* Known hypersensitivity to \\[¹⁸F\\]FAPI-74.\n* Administration of another investigational diagnostic or therapeutic product within 30 days prior to \\[¹⁸F\\]FAPI-74 administration.\n* Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of \\[¹⁸F\\]FAPI-74 administration.\n* Previous cancer (except basal cell carcinoma of the skin or in situ carcinoma of the cervix\u002Futerus (participants treated with curative intent and disease free for more than 5 years are permitted).\n* Hepatic function: T. bili \\>1.5X ULN or alk phos, ALT, or AST \\>5X ULN\n* Renal function: GFR \\\u003C 30 mL\u002Fmin\n* Pregnant or currently breast feeding (a negative pregnancy test is required in women of childbearing potential).\n* Inability to undergo the PET\u002FCT scanning procedure.\n* Inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Sarcoidosis\n* Treatment, including chemotherapy, radiation, immunotherapy or surgery for curative intent of Gastroesophageal cancers",{"count":169,"type":20},200,[115],"This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \\[¹⁸F\\]FAPI-74 PET\u002FCT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \\[¹⁸F\\]FAPI-74 PET\u002FCT screening. SOC procedures and interventions will be captured during 3 months +\u002F-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \\[¹⁸F\\]FAPI-74 PET\u002FCT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \\[¹⁸F\\]FAPI-74 PET\u002FCT.",[24,173,174],"Gastric Cancer (GC)","Gastroesophageal Junction",[176,177,178,179,180,181],"FAP","Fibroblast Activation Protein","Fibroblast Activation Protein Inhibitor","FAPI","gastroesophageal cancer","PET","2026-06-26",{"date":129,"type":31},{"date":185,"type":31},"2025-11-14",{"date":187,"type":20},"2027-08-30",{"name":189,"class":137},"SOFIE",15,{"id":192,"slug":4,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},"100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":200,"type":20},100,"This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[203,55,204,58,60,24,61,205,66,64,206,207,208,209,67,68,69,210,211,71,212,213,214,215,216,217,218],"Adenocarcinoma (NOS)","Bladder Cancer","Gastrointestinal Stromal Tumour","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer",{"date":220,"type":31},"2026-06-29",{"date":222,"type":31},"2025-09-18",{"date":224,"type":20},"2028-03-30",{"name":136,"class":137},17,{"id":228,"slug":4,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":233,"sex":16,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":238,"studyType":21,"phases":4,"briefSummary":239,"conditions":240,"keywords":270,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":237,"type":20},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[68,215,65,24,241,59,70,242,55,243,244,245,62,64,246,247,248,249,204,63,250,69,213,251,216,252,253,254,255,256,257,258,259,211,260,261,262,263,57,264,206,71,265,266,67,60,217,267,268,269],"Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[68,215,271,272,273,274,275,276,277,278,57,279,268,269],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":220,"type":31},{"date":283,"type":31},"2013-11-01",{"date":285,"type":20},"2099-12",{"name":287,"class":38},"University of Nebraska",42,{"id":290,"slug":4,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":49,"phases":298,"briefSummary":299,"conditions":300,"keywords":303,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100460527","NCT05276791","EMR Versus ESD for Barrett's Neoplasia","Endoscopic Mucosal Resection Versus Endoscopic subMucosal Dissection fOr Removal of Visible Lesions in Barrett's Esophagus With Early Neoplasia: a Randomized Controlled Trial","REMOVE-RCT","Inclusion Criteria:\n\n* Patients age: ≥ 18 years\n* Willingness to undergo both EMR or ESD\n* Ability to provide written, informed consent (approved by IRB) and understand the responsibilities of trial participation\n* BE with at least one visible lesion (\"target lesion\") with absence of signs of submucosal invasion on endoscopy, after evaluation by the adjudication committee\n* Multiple lesions are allowed as long as the lesions are considered eligible for endoscopic treatment. Only the target lesion is evaluated for the study\n* Prior endoscopic resection is allowed\n\nExclusion Criteria:\n\n* Patients with visible lesions with suspicion of submucosal invasion based on assessment of the adjudication committee\n* Patients with HGD in at least one random biopsy, before inclusion (i.e. during endoscopy in the referring center \\\u003C3 months before imaging, or during imaging endoscopy)\n* History of esophageal surgery other than fundoplication\n* History of esophageal ablation therapy\n* In case of prior endoscopic resection, the target lesion located within 1 cm of the prior resection site\n* Uncontrolled coagulopathy with INR \\>2.0, thrombocytopenia with platelet counts \\\u003C 50,000\n* Esophageal varix or varices\n* Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines\n* Life expectancy \\\u003C2 years",{"count":297,"type":20},331,[51],"Rationale:\n\nThe optimal technique for removal of visible dysplastic lesions in Barrett's esophagus remains controversial. Endoscopic mucosal resection (EMR) is safe, effective, easy to apply, and has been the most widely used technique since 2008. Endoscopic submucosal dissection (ESD) is a more controlled dissection method with potential improved efficacy, but at the cost of higher technical complexity.\n\nObjective:\n\nThe investigators aim to compare EMR and ESD for removal of visible lesions in Barrett's esophagus.\n\nStudy design:\n\nRandomized clinical trial\n\nStudy population:\n\nPatients with Barrett's esophagus and a visible lesion with dysplasia and\u002For early cancer. Suspicion for submucosal invasion is an exclusion criterion.\n\nIntervention:\n\nPatients are randomized to receive either EMR or ESD, with follow-up and no ablation during 12 months after the resection.\n\nMain study endpoint:\n\nPrimary endpoint is the proportion of patients with no evidence of residual or local recurrent neoplasia during 12 months follow-up after baseline.",[301,302,24],"Barretts Esophagus With Dysplasia","Barrett Adenocarcinoma",[304,305],"Barrett's esophagus","Esophagheal adenocarcinom","2026-06-24",{"date":220,"type":31},{"date":309,"type":31},"2023-01-17",{"date":311,"type":20},"2028-12-01",{"name":313,"class":38},"St. Antonius Hospital",6,{"id":316,"slug":4,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":49,"phases":324,"briefSummary":325,"conditions":326,"keywords":335,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100551821","NCT06465069","A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","A Phase 1a\u002F1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors","NEXUS-01","Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer\n  * Cohort A2\u002FB1\u002FB2: urothelial carcinoma\n  * Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, HNSCC (head and neck squamous cell carcinoma), esophageal cancer, pancreatic cancer, or prostate cancer\n* Prior Systemic Therapy Criteria:\n\n  * Cohort A1\u002FC: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies\n  * Cohort A2\u002FB1\u002FB2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.\n* Prior enfortumab vedotin specific requirements:\n\n  * Cohorts A1\u002FA2\u002FC: prior treatment with enfortumab vedotin is allowed, but not required\n  * Cohort B1: individual must be enfortumab vedotin naive in the advanced\u002Fmetastatic setting\n  * Cohort B2: individual must have received enfortumab vedotin in the metastatic\u002Fadvanced setting.\n* Measurability of disease\n\n  * Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)\n  * Measurable disease is required as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for all Cohorts. Cohort A1 may permit non-measurable disease as defined by RECIST v1.1\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled CNS metastases\n* Individual with uncontrolled hypercalcemia\n* Individual with uncontrolled diabetes\n* Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Recent thromboembolic event and\u002For clinically significant bleeding disorder\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms\n* History of pneumonitis\u002Finterstitial lung disease\n* History of Grade ≥3 skin toxicity when receiving enfortumab vedotin\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",{"count":323,"type":20},420,[149],"The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.",[327,328,329,330,331,332,24,68,67,58,333,69,334,204],"Metastatic Solid Tumor","Recurrent Solid Tumor","Advanced Solid Tumor","Urinary Bladder Neoplasm","Triple Negative Breast Cancer","Non-small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Renal Pelvis Cancer",[204,336,337,338,339,340,334,251,341,342,343,344,345],"Bladder Neoplasm","Bladder Urothelial Carcinoma","Urinary Bladder Cancer","Urinary Tract Cancer","Urothelial Neoplasms","Nectin-4","Antibody Drug Conjugate (ADC)","Triple Negative Breast Cancer (TNBC)","Non-small Cell Lung Cancer (NSCLC)","Head and Neck Squamous Cell Carcinoma (HNSCC)","2026-06-17",{"date":348,"type":31},"2026-06-18",{"date":350,"type":31},"2024-07-01",{"date":352,"type":20},"2027-05",{"name":354,"class":137},"Eli Lilly and Company",34,{"id":357,"slug":4,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":49,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":105},"100607330","NCT07187154","The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy","Inclusion Criteria:\n\n* The patient is aware and able to communicate in Mandarin;\n* There are smartphones；\n* Proficient in using WeChat mini programs.\n* Patients who were scheduled for esophageal cancer resection in participating centers were eligible for inclusion.\n\nExclusion Criteria:\n\n* Have cognitive impairment or psychiatric illness;\n* Refusal to participate",{"count":362,"type":20},300,[51],"1. Research methods Constructed the \"Manual for Graded Management of Postoperative Symptoms of Esophageal Cancer\" and developed continuous care Procedures.\n2. Randomised controlled studies were conducted to verify the effects of the procedure.",[24],"2026-06-14",{"date":368,"type":31},"2026-06-16",{"date":370,"type":31},"2026-05-02",{"date":372,"type":20},"2027-02-01",{"name":374,"class":38},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":376,"slug":4,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":49,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":105},"100642624","NCT07578571","A Phase 1 Study of IM-1617 in Participants With Advanced Cancer","A Phase 1 Study of IM-1617 in Participants With Advanced Malignancies","Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n2. Part A: Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:\n\n   * CRC, all subtypes\n   * NSCLC:\n\n     * Non-squamous cell carcinoma subtypes, such as adenocarcinoma\n     * Squamous cell carcinoma subtype\n   * Breast cancer (subtypes based on estrogen\u002Fprogesterone receptor and HER2 testing according to American Society of Clinical Oncology - College of American Pathologists guidelines):\n\n     * Triple-negative breast cancer\n     * HR+, HER2- subtype\n   * Esophageal, esophagogastric junction, and gastric cancer:\n\n     * Adenocarcinoma subtype\n   * Other histologies, if approved by the Medical Monitor, which may include: head and neck squamous cell carcinoma; cervical cancer; bladder cancer; squamous cell carcinoma subtype of esophageal, esophagogastric junction, and gastric cancer; HER2+ breast cancer\n3. Part B Cohorts - Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:\n\n   * Cohort B1: CRC, all subtypes\n   * Cohort B2: NSCLC\n\n     * Non-squamous cell carcinoma subtypes, such as adenocarcinoma\n     * Squamous cell carcinoma subtype\n   * Cohorts B3 and B4: Cohort-specific disease indications may include those listed for Part A\n4. Participants must have disease that is considered to be noncurative and meet the appropriate criteria below:\n\n   * Part A only: Participants have progressed on, were intolerant to, or have a contraindication to prior SOC treatments, with no satisfactory SOC treatment options available.\n   * Part B only:\n\n     * Cohort B1 (CRC):\n\n       * Participants must have previously progressed on, were intolerant to, or have a contraindication to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, bevacizumab, and for those with RAS wild-type tumors, an anti-epidermal growth factor receptor (EGFR)-directed monoclonal antibody in advanced disease setting.\n       * Participants with actionable biomarkers must have been treated with at least one prior appropriate biomarker-directed therapy.\n       * If any of these therapies was given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.\n     * Cohort B2 (NSCLC):\n\n       * Participants must have previously progressed on, were intolerant to, or have a contraindication to platinum-based chemotherapy and a programmed cell death-1 (PD-1)\u002Fprogrammed death ligand 1 (PD-L1) monoclonal antibody (given concurrently or sequentially with chemotherapy) in advanced disease setting.\n       * Participants with actionable biomarkers must have been treated with at least one prior appropriate targeted therapy.\n       * If any of these therapies was given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.\n     * Cohorts B3 and B4: Criteria will be specified based on the disease indications selected.\n5. Participants must have measurable disease as defined per RECIST v1.1\n\nExclusion Criteria:\n\n1. Previously treated with an antibody-drug conjugate (ADC) with a topoisomerase-1 (TOP1) inhibitor payload. Exception: Participants with NSCLC or breast cancer may have received up to one prior ADC with a TOP1 inhibitor payload\n2. History of anaphylactic reaction to TOP1 inhibitors (e.g., irinotecan) or TOP1 inhibiting ADCs\n3. Life expectancy \\\u003C 12 weeks\n4. Prior solid organ transplant\n5. Symptomatic ascites or pleural effusion\n6. Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n7. Known history of another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of recurrence for at least 2 years and approved by the Medical Monitor",{"count":382,"type":20},175,[149],"This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).\n\nThis study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.",[386,387,57,24,388,389],"Colorectal Cancer","Non-Small Cell Lung Cancer","Stomach Cancer","Cancer","2026-06-11",{"date":392,"type":31},"2026-06-15",{"date":394,"type":31},"2026-05-21",{"date":396,"type":20},"2029-01",{"name":398,"class":137},"Immunome, Inc.",{"id":400,"slug":4,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":49,"phases":407,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":421,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":425,"leadSponsor":427,"locationsCount":4},"100643245","NCT07638410","Prehabilitation in High-risk Oncologic Surgery","SURG-236: Prehabilitation in High-risk Oncologic Surgery: A Prospective Cohort Study","Inclusion Criteria:\n\n* Evidence of probable or confirmed primary or recurrent malignant neoplasm of any stage\n* Planned to undergo neoadjuvant chemotherapy or chemoradiation\n* Eligible surgical candidate for one of the following procedures: pancreatectomy, gastrectomy, esophagectomy, cystectomy, low anterior resection, abdominoperineal resection, or cytoreductive surgery with heated intraperitoneal chemotherapy\n* Age greater than 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Ability to understand and willingness to sign a written informed consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization document\n\nExclusion Criteria:\n\n* Unable to complete study requirements, such as attending a minimum of two visits for each specialty referral. This will be assessed at the final preoperative visit, at which time the participant may be discontinued from the study and replaced. Participants will not be excluded due to lack of insurance coverage for health psychology visits.\n* Does not proceed to surgery at an affiliated institution\n* Pregnant or breastfeeding",{"count":406,"type":20},180,[51],"The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery. Prehabilitation is supportive care given before surgery to help patients prepare physically, nutritionally, and emotionally.\n\nThe main questions this study aims to answer are:\n\n1. Does prehabilitation reduce the number of participants who die or have serious complications within 30 days after surgery?\n2. Does prehabilitation improve physical strength and fitness, nutritional status, emotional well-being, and quality of life before surgery?\n3. Does prehabilitation affect the length of the hospital stay after surgery, the time it takes to start additional cancer treatment after surgery, or the ability to complete recommended additional treatment?\n\nParticipants will take part in a prehabilitation program during their treatment period before surgery. The program includes visits with physical therapy, nutrition, and health psychology. Participants will meet with each specialty at least twice before surgery. They will also complete questionnaires and tests that measure physical function, diet and weight, emotional well-being, and quality of life. After surgery, information about recovery and additional cancer treatment will be collected from medical records for up to 120 days.\n\nResearchers will compare the outcomes of participants who receive the prehabilitation program with outcomes from similar patients who previously received care at Fox Chase Cancer Center but did not participate in this study.",[68,410,62,24,204,67,411],"Colo-rectal Cancer","Abdominal Surgery Complications",[413,414,415,416,417,418,419,420],"Prehabilitation","Preoperative Rehabilitation","Multimodal Prehabilitation","Major Abdominal Surgery","Oncologic Surgery","Neoadjuvant Therapy","Postoperative Complications","Cancer Surgery","NOT_YET_RECRUITING","2026-06-09",{"date":390,"type":31},{"date":392,"type":20},{"date":426,"type":20},"2030-03-15",{"name":428,"class":38},"Fox Chase Cancer Center",{"id":430,"slug":4,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":49,"phases":436,"briefSummary":437,"conditions":438,"keywords":442,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":454},"100569561","NCT06695845","A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)","Inclusion Criteria:\n\n1. Is at least 18 years of age inclusive at the time of signing the informed consent\n2. Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with HER2-targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required.\n3. HER2 overexpression (IHC 3+) must be determined by a sponsor designated central laboratory.\n4. All participants must have adequate tumor sample for submission to allow central HER2 testing.\n5. Presence of at least 1 measurable lesion as assessed by Independent Central Review (ICR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\n6. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Has a life expectancy of at least 3 months, in the opinion of the investigator.\n8. Participants with history of treated and stable CNS metastases are eligible, provided the following criteria are met:\n\n   1. Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS.\n   2. Participants with treated CNS metastases that are no longer symptomatic may be included in the study if they recovered to \\\u003C Grade 1 (CTCAE Version 5.0 or higher) or baseline from the acute toxic effect associated with the treatment \\> 7 days prior to Cycle 1 Day 1.\n   3. Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention.\n9. Adequate organ functions.\n10. Females of childbearing potential must have a negative pregnancy test result.\n11. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.\n\nExclusion Criteria:\n\n1. Has known or suspected leptomeningeal disease and\u002For untreated brain metastasis.\n2. Has uncontrolled or significant cardiovascular disease\n3. Has ongoing toxicity related to prior cancer therapy\n4. Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals.\n5. Has known Human Immunodeficiency Virus (HIV) infection.\n6. Has active hepatitis B or C infection.\n7. Has an active SARS-CoV-2 infection.\n8. Has a history of life-threatening hypersensitivity to monoclonal antibody (mAbs) or to recombinant proteins or excipients in the drug formulation of zanidatamab.\n9. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site.\n10. Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study.\n11. Prior treatment with HER2-targeted therapy (Cohort 1 only).\n12. Has a history of trauma or major surgery\n13. Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.\n14. Received zanidatamab at any time prior to the current study.\n15. Colorectal Cancer (CRC) participants with known KRAS\u002FNRAS and BRAF mutations.\n16. Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion.\n17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.\n18. Prior or concurrent invasive malignancy other than the disease under study, whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen.",{"count":169,"type":20},[150],"The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.",[57,62,24,439,386,60,332,67,440,211,68,441],"Gastroesophageal Cancer","Urothelial Carcinoma","HER-2 Protein Overexpression",[443,444,445],"JZP598","ZW25","HER2 IHC 3+ Overexpression Solid Tumors","2026-06-05",{"date":422,"type":31},{"date":449,"type":31},"2025-01-14",{"date":451,"type":20},"2027-12-31",{"name":453,"class":137},"Jazz Pharmaceuticals",28,{"id":456,"slug":4,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":49,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":479},"100483897","NCT05581004","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","A Phase Ia\u002FIb, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Life expectancy of at least 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy\n* Tumor specimen availability\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding or intention of becoming pregnant during the study or within 4 months after the final dose of enzelkitug, or 4 months after the final dose of pembrolizumab, or 5 months after the final dose of atezolizumab\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and\u002For radiotherapy, within 3 weeks prior to initiation of study treatment\n* Active hepatitis B (HBV) or hepatitis C (HCV) or tuberculosis\n* Positive test for human immunodeficiency virus (HIV) infection\n* Acute or chronic active Epstein-Barr virus (EBV) infection at screening\n* Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first enzelkitug infusion\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Active or history of autoimmune disease\n* Prior allogeneic stem cell or organ transplantation",{"count":462,"type":20},450,[149],"This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.",[466,467,468,206,469,24,62,58,386,440,470,471],"Locally Advanced or Metastatic Solid Tumors","NSCLC","HNSCC","TNBC","Clear Cell RCC","HCC",{"date":422,"type":31},{"date":474,"type":31},"2022-10-20",{"date":476,"type":20},"2028-07-31",{"name":478,"class":137},"Genentech, Inc.",41,{"id":481,"slug":4,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":49,"phases":487,"briefSummary":488,"conditions":489,"keywords":492,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":105},"100595982","NCT07039526","Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.","Inclusion Criteria:\n\n1. Male and Female patients 18 years of age and older\n2. Have a primary diagnosis, or a high clinical suspicion, of gastrointestinal, fore gut, pancreatic, hepatobiliary, esophageal malignancies and gyn malignancies planned for HIPEC\u002Fdebulking, warranting surgery.\n3. Are scheduled to undergo surgical intervention for tumor resection or diagnostic laparoscopy for assessment of disease burden.\n4. Willingness to stop the use of folate, folic acid, or folate-containing supplements within 48 hours before administration of Cytalux\n5. Willingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n\nExclusion Criteria:\n\n1. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject\n2. History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation.\n3. History of allergy to any of the components of CYTALUX™ (pafolacianine) injection\n4. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule",{"count":486,"type":20},50,[150],"The goal of clinical trial is to test an FDA approved drug called Pafolacianine that attaches to cancer cells and lights up when seen through a special camera system in adults with a suspected primary diagnosis, or a high clinical suspicion of gastrointestinal, fore gut, pancreatic, hepatobiliary, esophageal malignancies and gyn malignancies planned for HIPEC\u002Fdebulking, warranting surgery. The main question it aims to answer is:\n\n• Can CYTALUX™ (pafolacianine) injection used with near-infrared (NIR) fluorescent imaging improve the detection of malignant tissue in subjects undergoing surgical resection for cancer? Participants taking part in this study will receive the study medication. Then, during the surgery the investigator team will turn on the camera to evaluate if the tumor is visible with the help of the study medication. Taking part in this study will last about 2 months.",[24,490,491],"Gastrointestinal Cancers","Gynecologic Cancers",[493,494,495,496,497,498,499,500],"Pafolacianine","CYTALUX","Folate receptor-alpha","Near-infrared fluorescence imaging","Intraoperative imaging","Fluorescence-guided surgery","esophageal cancer","gastrointestinal cancer","2026-06-03",{"date":446,"type":31},{"date":504,"type":31},"2025-08-19",{"date":506,"type":20},"2027-12",{"name":508,"class":38},"John Waters",{"id":510,"slug":4,"hasResults":11,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":49,"phases":518,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":541},"100570708","NCT06710756","Lead-212 PSV359 Therapy for Patients With Solid Tumors","A Phase I\u002FIIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Satisfactory organ function as determined by laboratory testing\n* Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1\n* Life expectancy \\> 3 months\n* Progressive disease despite standard therapy or for whom no standard therapy exists\n* Positive \\[203Pb\\]Pb-PSV359 SPECT\u002FCT scan showing uptake of \\[203Pb\\]Pb-PSV359 in at least 1 known lesion on the 1-hour SPECT\u002F CT scan\n* Histological, pathological, and\u002For cytological confirmation of solid tumor malignancy that is locally advanced or metastatic\n\nExclusion Criteria:\n\n* Known hypersensitivity to the active agent or any of the excipients\n* Active secondary malignancy\n* Pregnancy or breastfeeding a child\n* Known brain metastases\n* Known active or uncontrolled infections requiring ongoing antifungals or antibiotics in the 3 days prior to enrollment\n* Known medical condition which would make this protocol unreasonably hazardous for the patient\n* Existence of any medical or social issues likely to interfere with study conductor that may cause increased risk to the subject or to others, e.g., lack of ability to follow radiation safety precautions\n* Medical history of a condition resulting in a severe allergic reaction such as anaphylaxis or angioedema to known components of the investigational product or excipients\n* Major surgery within 21 days prior to the administration of \\[212Pb\\]Pb-PSV359; the subject must be sufficiently recovered and stable before treatment administration\n* Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to enrollment into the study\n* Current abuse of alcohol or illicit drugs\n* Treatment with any live\u002Fattenuated vaccine in the 7 days prior to enrollment\n* Previous treatment with any systemic anticancer therapy within 4 weeks prior to treatment on study","90 Years",{"count":517,"type":20},112,[149,150],"Phase I\u002FIIa image-guided, alpha-particle therapy study of \\[203Pb\\]Pb-PSV359 and \\[212Pb\\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.",[521,62,24,386,67,66,71,263],"Pancreatic Ductal Adenocarcinoma",[177,523,524,271,525,526,527,528,529,530,531,532,533],"Solid tumor malignancy","Gastric cancer","Colorectal cancer","Ovarian cancer","Head and neck cancer","Theronostic","Radiopharmaceutical","Radiotherapy","Alpha Particle","Pb-203","Pb-212",{"date":446,"type":31},{"date":536,"type":31},"2025-04-28",{"date":538,"type":20},"2032-05-28",{"name":540,"class":137},"Perspective Therapeutics",8,{"id":543,"slug":4,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":11,"sex":16,"minAge":547,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":548,"phases":4,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":563,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":567,"locationsCount":569},"100405976","NCT04566393","Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","Inclusion Criteria:\n\n* Main Inclusion Criterion:\n\n  1\\. Patient has a MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations.\n* Other Inclusion Criteria:\n\n  1. In the opinion of the treating physician, the patient has exhausted or has inadequate response to available anti-cancer treatments.\n  2. In the opinion of the treating physician, the patient has adequate organ function to tolerate ulixertinib as defined in section 6.1\n  3. Male or female patients aged ≥ 12 years.\n  4. Patient must be able to swallow and retain orally administered medication.\n\n     Note: Ulixertinib is primarily absorbed in the duodenum and therefore patients with any prior stomach or duodenal resection should be evaluated with that understanding.\n  5. For females, evidence of post-menopausal status or negative urinary or serum pregnancy test for pre-menopausal patients.\n  6. Highly effective contraception for both male and female patients throughout the treatment and for at least 4 months after last treatment administration. In patients under the age of 18, who are not sexually active, abstinence is an acceptable form.\n  7. Toxicities related to any prior treatments are either stable, stable on supportive therapy, resolved, or in the opinion of the treating physician, clinically non-significant\n  8. Ability to understand a written informed consent document, and the willingness to sign it. Assent will be obtained when appropriate based on the patient's age.\n\nExclusion Criteria:\n\n1. Patient is already participating in or qualifies for and is able to enroll in a clinical trial of ulixertinib (BVD-523).\n2. Patient has received systemic therapy with an investigational agent within 5 half-lives or 14 days prior to starting ulixertinib treatment, whichever is shorter.\n3. Patient has received radiotherapy within 14 days prior to the first dose of ulixertinib treatment other than for the allowable treatment of symptomatic bone metastasis.\n4. A history of current evidence\u002Frisk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)\n5. Current evidence of uncontrolled, significant intercurrent illness that would, in the treating physician's judgment, contraindicate the patient's treatment with ulixertinib due to safety concerns.\n6. Patients who, in the opinion of the treating physician, have not fully recovered from recent major surgery to a sufficient extent to tolerate treatment with ulixertinib.\n7. Known hypersensitivity to ulixertinib or any component in its formulation.\n8. Patients taking prohibited medications as described in current Investigator's Brochure.\n\n   Note: Patients who require treatment with Drugs that are strong inhibitors or inducers of CYP1A2, CYP2D6, and CYP3A4 (see Appendix 3) were excluded from the FIH study of ulixertinib and should be discussed with xCures to review if any potential benefits outweigh the potential risks.\n9. Patient is actively breastfeeding.\n10. Prior stomach or duodenal resection that in the opinion of the treating physician would affect the breakdown and absorption of ulixertinib.","12 Years","EXPANDED_ACCESS","The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.\n\nUlixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.",[68,551,386,206,552,215,204,66,62,24,553,67,554,555,556,557,558,559,560,561,562],"Small Bowel Cancer","Non Small Cell Lung Cancer","Cholangiocarcinoma","Hepatocellular Carcinoma","Glioblastoma","MAPK Gene Mutation","KRAS Activating Mutation","BRAF Gene Mutation","NRAS Gene Mutation","HRAS Gene Mutation","MEK Mutation","ERK Mutation","AVAILABLE","2026-06-02",{"date":566,"type":31},"2026-06-04",{"name":568,"class":137},"xCures",26,{"id":571,"slug":4,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":11,"sex":16,"minAge":234,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":49,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":421,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":4},"100586333","NCT06914011","Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","Multi-center, Randomized, Phase III Trial of Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma (MRD2START)","MRD2START","Inclusion Criteria:\n\n* 1\\. Be willing and able to provide written informed consent. 2. Be ≥19 years of age on the day of signing the informed consent form. 3. Have ECOG performance status of 0 or 1 (Appendix 1). 4. Have a histologically confirmed diagnosis of squamous cell carcinoma of the esophagus\n\n  * Patients with tumors of mixed histology (i.e., squamous and non-squamous) are eligible if the predominant histological component is squamous, except when small cell or neuroendocrine elements are present.\n\n    5\\. Must have completed surgical resection for localized disease, either with prior neoadjuvant therapy (chemotherapy or chemoradiotherapy) or without prior neoadjuvant therapy (i.e., upfront surgery), in accordance with the 8th edition of the AJCC staging system (Appendix 2). Exceptionally, cases with supraclavicular lymph node metastasis as the only M1 lesion are also eligible if the lymph node has been surgically removed.\n\n    6\\. Must have undergone curative surgery (R0 resection) with negative margins on the resected specimen.\n\n    7\\. Complete resection must have been performed between 4-16 weeks before randomization.\n\n    8\\. Must have a documented disease-free status based on a complete physical examination and imaging studies within 4 weeks before randomization. Imaging studies must include CT scans (or MRI) of the chest, abdomen, and pelvis.\n\n    9\\. Must provide tumor tissue from pre-treatment biopsy (i.e., a biopsy obtained prior to neoadjuvant therapy in cases where neoadjuvant therapy is followed by surgery) or from surgical specimens and baseline blood samples for post-surgery ctDNA-MRD measurement and biomarker analyses.\n  * For patients who underwent upfront surgery, surgical tissue is preferred.\n  * For those who received neoadjuvant therapy followed by surgery, pre-treatment biopsy tissue is required. If pre-treatment biopsy tissue is unavailable or inadequate, submission of surgical specimens may be permitted following approval by the Study Sponsor.\n  * A FFPE tumor specimen in a paraffin block or 20 (at least 10, with a thickness of 10 µm) freshly cut unstained FFPE slides, along with one H\\&E-stained slide, must be submitted with the associated pathology report. If an insufficient number of slides is available, the decision on patient enrollment can be made in consultation with the Study Sponsor.\n  * Peripheral blood of approximately 4 mL must be collected for germline DNA analysis.\n  * Peripheral blood of approximately 20 mL must be collected between 3 to 12 weeks after curative surgery for ctDNA testing.\n\n    10\\. Must be confirmed to have MRD-positive status via postoperative baseline ctDNA testing.\n\n    11\\. Must have adequate major organ functions as demonstrated by the following laboratory results obtained within 14 days before randomization (these criteria must also be met within 7 days before initiating study treatment in the adjuvant therapy arm):\n  * Adequate bone marrow function defined by:\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FμL without granulocyte colony-stimulating factor support within 7 days before laboratory testing\n* Platelet count ≥ 100 ×103\u002FμL without transfusion within 7 days before laboratory testing\n\n  * Adequate renal function defined by:\n* Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 50 mL\u002Fminute, calculated using the Cockcroft-Gault formula (Appendix 3) or measured by a 24-hour urine collection\n\n  • Adequate hepatic function defined by:\n* ALT and AST ≤ 2.5 × ULN\n* Total bilirubin ≤ 1.5 × ULN, except for subjects with Gilbert syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who must have a total bilirubin level ≤ 3 × ULN 12. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to randomization. If the urine test is positive or inconclusive, a serum pregnancy test will be required.\n\n  13\\. Female subjects of childbearing potential randomized to the adjuvant therapy arm must agree to use an adequate method of contraception for the duration of study treatment and for 90 days after the last dose of study treatment.\n\n  14\\. Non-sterile male subjects randomized to the adjuvant therapy arm with female sexual partner(s) of childbearing potential must agree to use an adequate method of contraception for the duration of study treatment and for 90 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* 1\\. Documented recurrence of esophageal cancer before randomization following curative resection.\n\n  2\\. Receipt of any treatment aimed at the resected esophageal cancer after curative surgery, including chemotherapy, targeted therapy, immunotherapy, radiotherapy, biologic therapy, investigational agent, or local therapies, except for procedures intended for palliative care (e.g., stent insertion, balloon dilatation, or feeding enterostomy).\n\n  3\\. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor, or any other drug targeting T-cell co-stimulation or checkpoint pathways.\n\n  4\\. Active autoimmune disease requiring systemic treatment within the 2 years prior to study entry (i.e., using disease-modifying agents, corticosteroids, or immunosuppressive drugs).\n  * Replacement therapy (e.g., thyroxine for autoimmune-related hypothyroidism, insulin for type 1 diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n\n    5\\. Condition requiring systemic treatment with corticosteroids (\\>10 mg daily prednisone or equivalent) or any other form of immunosuppressive therapy within 14 days prior to study entry.\n  * Use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroids is permitted if there is no active autoimmune disease.\n  * A short course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergens) is permitted.\n\n    6\\. Receipt of a live vaccine within 28 days prior to study entry.\n  * COVID-19 vaccines are allowed except for any live vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.\n\n    7\\. Active infection requiring systemic therapy within 14 days prior to study entry.\n\n    8\\. History of severe hypersensitivity to paclitaxel, carboplatin, or any antibody products.\n\n    9\\. Known history of, or any evidence of, interstitial lung disease, non-infectious pneumonitis, or pulmonary fibrosis diagnosed based on imaging or clinical findings.\n  * Subjects with radiation pneumonitis may be enrolled if radiation pneumonitis is stable (beyond the acute phase) and unlikely to recur.\n\n    10\\. History of allogeneic stem cell or solid organ transplantation. 11. Malignancies other than esophageal cancer within the 3 years prior to study entry, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%), such as adequately treated non-melanoma skin cancer, superficial bladder cancer, or carcinoma in situ (e.g., cervix, breast, or prostate).\n  * Subjects who received endoscopic mucosal resection or dissection for superficial mucosal cancers within the past 3 years are eligible.\n\n    12\\. Subjects with toxicities attributed to prior anti-cancer therapy, except alopecia, anorexia, fatigue, and hearing loss, that have not resolved to Grade 1 (NCI CTCAE v5.0) or baseline before randomization will be excluded.\n\n    13\\. Significant cardiovascular impairment within 6 months prior to study entry, including a history of congestive heart failure (New York Heart Association Class III or IV), unstable angina, myocardial infarction, cerebrovascular accident, or cardiac arrhythmia associated with hemodynamic instability.\n\n    14\\. Any serious or uncontrolled medical disorder that, in the investigator's opinion, may increase the risk associated with study participation or study treatment administration, or compromise the subject's ability to receive protocol therapy.\n\n    15\\. History or current evidence of any condition, therapy, or laboratory abnormality that could confound trial results, interfere with the subject's participation for the full trial duration, or is not in the best interest of the subject to participate, in the investigator's opinion.\n\n    16\\. Medical or psychiatric conditions that impair the subject's ability to give informed consent or complete the protocol, or a history of non-compliance.\n\n    17\\. Known history of Human Immunodeficiency Virus (HIV) infection. 18. Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers with HBV DNA ≥500 IU\u002FmL (or 2,500 copies\u002FmL), or active hepatitis C virus (HCV) infection:\n  * Subjects with chronic hepatitis B (HBV DNA \\\u003C 500 IU\u002FmL or \\\u003C 2,500 copies\u002FmL) who are receiving antiviral therapy can be enrolled. Patients with detectable HBsAg or detectable HBV DNA should be managed according to institutional guidelines.\n  * Patients with a negative HCV antibody test result at screening or a positive HCV antibody test followed by a negative HCV RNA test result at screening are eligible.\n\n    19\\. Pregnant or breastfeeding women 20. Any condition requiring treatment with prohibited or restricted concomitant medication or therapy as described in Section 6.2.2",{"count":578,"type":20},172,[115],"This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with curatively resected esophageal squamous cell carcinoma.",[24],"2026-05-29",{"date":564,"type":31},{"date":585,"type":20},"2026-05-06",{"date":587,"type":20},"2034-05-30",{"name":589,"class":38},"Asan Medical Center",{"id":591,"slug":4,"hasResults":11,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":49,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":610},"100493390","NCT05704530","Liquid Biopsies in Esophageal Cancer","Personalized Multimodal Treatment for Resectable Esophageal Cancer by Detecting Minimal Residual Disease Using Circulating Tumor DNA: a Multicentric Prospective Study","Key inclusion criteria are:\n\n1. Male or female, age \\> 18 years\n2. New diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (ESCC) or adenocarcinoma (EAC)\n3. Clinically staged - cT1-4 N0-2 M0 (local or locally advanced, resectable)\n4. Eligible for multidisciplinary treatment as assessed by MDT\n5. Able to provide informed consent (ICF) according to Good Clinical Practice and national\u002FEuropean regulations\n\nKey exclusion criteria are:\n\n1. (Oligo)metastatic disease\n2. Histologically or cytologically confirmed diagnosis other than squamous cell carcinoma or adenocarcinoma (eg. neuroendocrine carcinoma, lymphoma…)\n3. Other active malignancies\n4. Previous exposure to chemoradiation (prior to MDT)\n5. Treatment plan after MDT: neoadjuvant chemotherapy with no radiation or chemoradiation with definitive intent (surgery is not planned)",{"count":597,"type":20},248,[51],"Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.",[24],"2026-05-27",{"date":603,"type":31},"2026-06-01",{"date":605,"type":31},"2023-03-29",{"date":607,"type":20},"2029-12-31",{"name":609,"class":38},"Universitaire Ziekenhuizen KU Leuven",4,{"id":612,"slug":4,"hasResults":11,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":4,"eligibilityCriteria":616,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":145,"enrollmentInfo":617,"targetDuration":4,"studyType":49,"phases":619,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":105},"100605437","NCT07162506","DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR\u002FPR After nCI","Definitive Concurrent Chemoradiotherapy Versus Surgery in Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (ESCC) Who Achieve Complete or Partial Response After Neoadjuvant Chemo-immunotherapy: A Two-arm Phase II Clinical Study (SORT Trial)","Inclusion Criteria:\n\n1. Volunteered to participate, cooperated with follow-up visits.\n2. Aged 18 - 75 years (inclusive), male or female.\n3. Histologically confirmed locally advanced resectable ESCC, clinically staged as Stage II - IVa (cT1N1-3M0, cT2-4aN0-3M0 before treatment; 8th AJCC), and achieve cCR\u002FPR after 2-3 cycles of platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies.\n4. Presence of measurable and\u002For non-measurable lesions as defined by Japanese Classification of Esophageal Cancer (12th Edition);\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n6. Estimated survival time ≥ 3 months.\n7. The function of major organs meets the following requirements:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL;\n   2. Platelets ≥ 80×10\\^9\u002FL;\n   3. Hemoglobin ≥ 9g\u002FdL;\n   4. Serum albumin ≥ 2.8g\u002FdL;\n   5. Total bilirubin ≤ 1.5 × ULN, ALT, AST and\u002For ALP ≤ 2.5 × ULN;\n   6. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60mL\u002Fmin;\n   7. International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5× ULN (subjects on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, and with INR within the expected therapeutic range of the anticoagulant can be screened);\n8. Comprehensive baseline staging evaluation prior to induction chemo-immunotherapy, including esophagogastroduodenoscopy (with biopsy) and\u002For endoscopic ultrasonography (EUS), contrast-enhanced CT of the neck, chest, and upper abdomen (with or without PET-CT), magnetic resonance imaging (MRI) without MRI contraindications, and upper gastrointestinal contrast.\n9. Patients of childbearing potential must use a medically approved contraceptive method (such as intrauterine device, contraceptive pills, or condoms) during the study treatment period and within 6 months after the end of the study treatment; serum Human Chorionic Gonadotropin (HCG) or urine HCG test must be negative within 72 hours before study enrollment; and must not be breastfeeding.\n\nExclusion Criteria:\n\n1. Surgery for esophageal cancer;\n2. Esophageal fistulae due to infiltration of the primary tumor；\n3. Risk of gastrointestinal bleeding, esophageal fistula or esophageal perforation;\n4. Poor nutritional status, weight loss of ≥10% in the previous 2 months, with no significant improvement after nutritional intervention;\n5. Major surgery or severe trauma within 4 weeks prior to first use of study drug;\n6. Uncontrollable pleural effusion, pericardial effusion, or ascites that requires repeated drainage;\n7. Received or receiving any of the following treatments in the past:\n\n   1. Radiotherapy or targeted therapy;\n   2. Participation in a study of an investigational agent or device within 4 weeks before the first dose of study treatment;\n   3. Systemic treatment with corticosteroids (\\>10 mg prednisone equivalent dose per day) or other immunosuppressive agents is required for 2 weeks before the first dose of study treatment (except for the use of corticosteroids for local inflammation of the esophagus and for the prevention of allergy and nausea and vomiting). Other special circumstances need to be communicated to the sponsor. Inhaled or topical steroids and adrenocorticotropic hormone replacement at doses \\>10mg\u002Fday prednisone efficacy dose are permitted if the patient does not have active autoimmune disease;\n   4. Received an anti-tumour vaccine or received a live vaccine within 4 weeks before the first dose of study treatment;\n8. Any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonitis, uveitis, enteritis, hepatitis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Except for patients with vitiligo or those who had asthma or allergies in childhood but did not need any intervention as adults; patients with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone and type I diabetes mellitus treated with stable doses of insulin may be included;\n9. Diagnosis of immunodeficiency, including positive HIV test, other acquired\u002Fcongenital immunodeficiency diseases, organ transplantation and allogeneic bone marrow transplantation;\n10. Diagnosis of uncontrolled cardiac clinical symptoms or disease such as: a. NYHA II or above heart failure; b. unstable angina; c. myocardial infarction within 1 year; d. clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;\n11. Severe infections (CTCAE \\> grade 2), such as severe pneumonia requiring hospitalisation, bacteraemia, infectious co-morbidities, etc., within 4 weeks before the first use of study treatment; Baseline chest imaging suggestive of active lung inflammation, signs and symptoms of infection requiring oral or intravenous antibiotic treatment within 2 weeks before the first use of study treatment, except for prophylactic antibiotic use;\n12. History of interstitial lung disease or non-infectious pneumonia, or pulmonary insufficiency ≥ grade 3 as confirmed by pulmonary function tests;\n13. Active tuberculosis infection detected by history or CT examination, or history of active tuberculosis infection within 1 year before enrollment or more than 1 year previously without regular treatment;\n14. Presence of active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 104 copies\u002FmL), hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower limit of detection);\n15. Presence of abnormal sodium, potassium, and calcium laboratory test values greater than grade 1 within 2 weeks prior to enrollment that do not improve with treatment;\n16. Known hypersensitivity to large protein preparations, or to any of the components of camrelizumab, or anaphylaxis, hypersensitivity, or contraindication to paclitaxel or carboplatin or to any of the components used within their preparations;\n17. Previously diagnosed with any other malignancy within 5 years before the first use of the investigational drug, except for malignancies with low risk of metastasis and death (5-year survival rate\\>90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.\n18. As judged by the investigator, the subject has other factors that may lead to forced termination of the study midway.",{"count":618,"type":20},120,[150],"This is a multi-center, Phase II clinical study aiming to evaluate the efficacy, safety, and organ preservation feasibility of definitive concurrent chemoradiotherapy versus surgery in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) who achieve clinical complete response\u002Fpartial response (cCR\u002FPR) after neoadjuvant chemo-immunotherapy.\n\nA total of 120 eligible subjects will be enrolled. Patients with cCR\u002FPR after 2-3 cycles of neoadjuvant chemo-immunotherapy will be grouped based on personal willing: the control group (n=60) will receive radical esophagectomy + mediastinal lymph node dissection; the experimental group (n=60) will receive definitive concurrent chemoradiotherapy (radiotherapy: 50.4 Gy\u002F28f; chemotherapy: nab-paclitaxel 175mg\u002Fm² + carboplatin AUC=5, q21d for 2 cycles). All the patients will receive camrelizumab maintenance therapy (200mg q21d) up to 1 year.",[24],"2026-05-26",{"date":582,"type":31},{"date":625,"type":31},"2025-11-03",{"date":627,"type":20},"2030-08-30",{"name":629,"class":38},"Tianjin Medical University Cancer Institute and Hospital",{"id":631,"slug":4,"hasResults":11,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":4,"eligibilityCriteria":635,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":636,"targetDuration":4,"studyType":49,"phases":638,"briefSummary":639,"conditions":640,"keywords":643,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":658},"100525561","NCT06123338","A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer","A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab With Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors","Inclusion Criteria:\n\n* Age 18 years or older at time of signing informed consent.\n* ECOG performance status 0-1.\n* HER2+ esophageal, GEJ, or gastric adenocarcinoma biopsy or resection specimen as defined by local HER2 IHC3+ or IHC 2+\u002FFISH\\>2.0 expression.\n* Complete surgical resection of the primary tumor must be achievable\n* Demonstrate adequate organ function as defined in Table 1.\n\nTable 1 - Organ Function Requirements for Eligibility Hematological\n\n* Absolute neutrophil count (ANC): ≥1,500 \u002FmcL\n* Platelets: ≥100,000 \u002F mcL\n* Hemoglobin: ≥8 g\u002FdL Renal\n* Creatinine clearance: ≥ 50 mL\u002Fminute Hepatic\n* Serum total bilirubin: ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \\> 1.5 ULN. Except patients with Gilbert's disease (≤3x ULN)\n* AST and ALT: ≤ 2.5 X ULN\n* Albumin: \\>3 mg\u002FdL Coagulation\n* International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT): \\\u003C1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n* Male participants: A male participant must agree to use contraception as detailed in Section 15.3 of this protocol during the treatment period and for at least 230 days (5 terminal half-lives of trastuzumab \\[140\\] plus an additional 90 days \\[spermatogenesis cycle\\]) after the last dose of study treatment and refrain from donating sperm during this period.\n* Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n  1. Not a woman of childbearing potential (WOCBP) as defined in section 15.3 OR\n  2. A WOCBP who agrees to follow the contraceptive guidance in section 15.3 during the treatment period and for at least 170 days (140 days plus an additional 30 days \\[menstruation cycle\\]) after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Presence of metastatic or recurrent disease.\n* Has received prior treatment for esophagogastric cancer\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.\n* Has received prior therapy with an anti-HER2 agent\n* Left ventricular ejection fraction \\\u003C50% within 1 month of screening by MUGA or echocardiogram. Patients with an ejection fraction 45-49% may be permissible in the absence of any cardiac symptoms, if cleared by a cardiologist, and per the investigator's discresion.\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast premedication) may be enrolled.\n* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.\n* Has a known history of active TB (Bacillus tuberculosis)\n* Hypersensitivity to pembrolizumab or any of its excipients\n* Has been diagnosed or treated for another malignancy in the past 3 years (not including non-melanoma skin cancer)\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has known history of, or any evidence of active, non-infectious pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Has had an allogeneic tissue or solid organ transplant\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease; systemic lupus erythematosus; Wegener syndrome \\[granulomatosis with polyangiitis\\]; myasthenia gravis; Graves' disease; rheumatoid arthritis, hypophysitis, uveitis) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:\n\n  * Subjects with vitiligo or alopecia\n  * Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment.\n  * Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies).\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.\n* Is unwilling to give written informed consent, unwilling to participate, or unable to comply with the protocol for the duration of the study.",{"count":637,"type":20},49,[150],"The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.",[24,641,642],"Gastric Adenocarcinoma","HER2 Gene Mutation",[644,24,641,645,646,647,648,649,650],"HER2+ Esophageal cancer","HER2+ GEJ cancer","HER2 IHC3+ expression","IHC 2+\u002FFISH>2.0 expression","Esophagogastric cancer","Memorial Sloan Kettering Cancer Center","23-124",{"date":652,"type":31},"2026-05-28",{"date":654,"type":31},"2024-02-01",{"date":656,"type":20},"2027-11-30",{"name":649,"class":38},10,{"id":660,"slug":4,"hasResults":11,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":4,"eligibilityCriteria":664,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":49,"phases":667,"briefSummary":668,"conditions":669,"keywords":672,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":676,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":683},"100552196","NCT06469944","Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable\u002FMetastatic Gastroesophageal Adenocarcinoma (MK-3475-06C\u002FKEYMAKER-U06)","A Phase 1\u002F2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\u002FMetastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically and\u002For cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic first-line (1L) gastroesophageal adenocarcinoma\n* Is not expected to require tumor resection during the treatment course\n* Tumor tissue must be confirmed as negative for human epidermal growth factor receptor 2 (HER2) expression as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines\n* Core\u002Fexcisional biopsy of a tumor lesion not previously irradiated has been provided\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline\n* Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible\n* Has adequate organ function\n* Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as determined by the local site investigator\u002Fradiology assessment and verified by blinded independent central review (BICR)\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days prior to the first dose of study intervention\n* Has a life expectancy of at least 6 months\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization\n* Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has squamous cell or undifferentiated gastroesophageal cancer.\n* Has had previous therapy for locally advanced unresectable or metastatic gastric\u002Fgastroesophageal junction (GEJ)\u002Fesophageal adenocarcinoma\n* Has experienced weight loss \\>20% over 3 months before the first dose of study intervention\n* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing\n* Has Grade ≥2 peripheral neuropathy\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within 6 months preceding study intervention\n* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment\n* Has history of human immunodeficiency virus (HIV) infection with Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has received prior treatment with a trophoblast antigen 2 (TROP2)-targeted or anti-human epidermal growth factor receptor 3 (HER3) targeted agents\n* Has received prior treatment with a topoisomerase I inhibitor-based antibody-drug conjugate (ADC) and\u002For a topoisomerase I inhibitor-based chemotherapy\n* Has received prior systemic anticancer therapy within 4 weeks before the first dose of study intervention\n* Has received prior therapy with an anti-Programmed Cell Death Protein 1 (PD-1), anti-Programmed Cell Death-Ligand 1 (PD-L1), anti-Programmed Cell Death-Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR)\n* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation related toxicities, requiring corticosteroids\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Has received a strong inducer\u002Finhibitor of CYP3A4 that cannot be discontinued\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has Severe hypersensitivity (≥Grade 3) to pembrolizumab, sacituzumab tirumotecan, patritumab deruxtecan, or other biologic therapy, chemotherapy (ie, oxaliplatin, fluorouracil, capecitabine), leucovorin, levoleucovorin, or any of their excipients\n* Has active autoimmune disease that has required systemic treatment in the past 2 years\n* Has history of (noninfectious) pneumonitis or interstitial lung disease (ILD) that required steroids or has current pneumonitis or ILD, or where suspected ILD or pneumonitis cannot be ruled out by imaging at screening\n* Has an active infection requiring systemic therapy\n* Has concurrent active hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] positive and\u002For detectable HBV DNA) and hepatitis C virus (defined as anti-hepatitis C virus \\[HCV\\] Ab positive and detectable HCV ribonucleic acid \\[RNA\\] infection or a known history of hepatitis B and\u002For C infection\n* Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's ability to cooperate with the requirements of the study\n* Has gastrointestinal (GI) obstruction, poor oral intake, or difficulty in taking oral medication\n* Has poorly controlled diarrhea\n* Has had a major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention\n* Has history of allogeneic tissue\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery or has ongoing surgical complications",{"count":666,"type":20},160,[149,150],"This is a phase 1\u002F2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma.\n\nThis substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.",[174,670,671,24],"Gastroesophageal Adenocarcinoma","Esophageal Neoplasms",[673,674,675],"Programmed Cell Death-1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)",{"date":622,"type":31},{"date":678,"type":31},"2024-09-20",{"date":680,"type":20},"2029-09-12",{"name":682,"class":137},"Merck Sharp & Dohme LLC",51,{"id":685,"slug":4,"hasResults":11,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":4,"eligibilityCriteria":689,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":690,"targetDuration":4,"studyType":49,"phases":692,"briefSummary":693,"conditions":694,"keywords":696,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":701,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":105},"100583145","NCT06872515","Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)","Impact of Prehabilitation in Oncology Via Exercise- Esophageal","Inclusion Criteria:\n\n* Men and women, age ≥ 18 years old\n* Diagnosed with esophageal cancer\n* Identified as esophagectomy surgery candidates at Hillman Cancer Center, UPMC Shadyside, or UPMC Passavant\n* ≥ 2 weeks until scheduled esophagectomy\n* ECOG Performance Status Scale score of ≤ 2\n* Ability to provide written informed consent\n* Ability to understand, speak, and read English.\n\nExclusion Criteria:\n\n* Evidence in the medical record of an absolute contraindication for exercise (e.g., Heart insufficiency \\> NYHA III or uncertain arrhythmia; uncontrolled hypertension; reduced standing or walking ability)\n* Any other comorbidities or musculoskeletal complications that preclude participation in the exercise programs as deemed by the exercise interventionist\n* Receiving non-esophagectomy related chemotherapy and\u002For radiotherapy\n* Active infections, hemorrhages, and cytopenias that could place surgical patients at risk for further adverse events, deemed by the exercise interventionist, physician, and\u002For nurse",{"count":691,"type":20},20,[51],"The goal of this study is to determine the feasibility of a prehabilitation exercise and nutrition program (exercise and nutrition before a medical treatment) in adults with esophageal cancer before surgery (esophagectomy). The pre-surgery exercise and nutrition program will include resistance and aerobic training and nutrition supplementation during the weeks before surgery. We will also assess pre-surgical care needs in adults with esophageal cancer. Researchers will compare the exercise and nutrition intervention to usual care- which is standard medical care and post-surgery surveillance\u002Ffollow-up to understand the impact of exercise and nutrition before surgery. We will follow-up with participants before surgery, and after surgery at 2 weeks, 6 weeks, and 4-months at appointments that coincide with clinical follow-ups.\n\nThe main questions of this trials are:\n\n* Is exercise and nutrition supplementation before surgery for esophageal cancer feasible and acceptable to patients?\n* How does exercise and nutrition supplementation before surgery change physical function and psychosocial health?\n* What are important pre-surgical needs for adults with esophageal cancer?",[24,695],"Esophageal Carcinoma",[413,697,271,698,699],"Exercise","Neoadjuvant chemotherapy","Pre-surgical exercise","2026-05-20",{"date":622,"type":31},{"date":703,"type":31},"2025-07-16",{"date":705,"type":20},"2027-10-01",{"name":707,"class":38},"University of Pittsburgh",{"id":709,"slug":4,"hasResults":11,"nctId":710,"briefTitle":711,"officialTitle":712,"acronym":4,"eligibilityCriteria":713,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":714,"targetDuration":715,"studyType":21,"phases":4,"briefSummary":716,"conditions":717,"keywords":719,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":722,"lastUpdatePostDateStruct":723,"startDateStruct":725,"completionDateStruct":727,"leadSponsor":729,"locationsCount":105},"100559027","NCT06558786","Registry for Esophageal and Gastroesophageal Junction Cancer","Prospective Registry Study of Multimodality Therapy for Oligometastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction","Inclusion Criteria:\n\n* Newly diagnosed stage IV adenocarcinoma of the esophagus or GEJ with OMD at the time of diagnosis, defined as the following:\n* Retroperitoneal lymph nodes (e.g., para-aortal, intra-aorto-caval, parapancreatic, or mesenterial lymph node)\n* Liver\n* Lung\n* Extra-abdominal lymph nodes (e.g., supraclavicular or cervical lymph nodes)\n* Adrenal gland\n* Unilateral or bilateral ovarian metastases (in the absence of gross or microscopic peritoneal disease \\[positive cytology\\])\n* Bone\n* ≤2 sites of disease (excluding the primary tumor and regional lymph nodes)\n* ≤3 tumors within each organ system\n* ≤5 metastases\n* All nonregional lymph nodes (including cervical, supraclavicular, and retroperitoneal nodal disease) are considered 1 discrete lesion\n* Satellite lesions in the primary esophageal malignancy, such as skipped esophageal primaries, are not considered metastatic sites\n* All sites of disease must be amenable to complete local therapy after systemic therapy, according to the treating physician. Treatment modalities include:\n* Surgery\n* Definitive chemoradiation\n* Stereotactic radiation\n* Ablation or similar techniques (e.g., irreversible electroporation)\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Presence of metastases, at the time of diagnosis, to the following:\n\n  * Peritoneum, including positive peritoneal lavage (on the basis of baseline diagnostic laparoscopy to rule out gross disease and positive peritoneal lavage cytology; laparoscopy may be omitted for patients in whom all sites of disease are above the diaphragm)\n  * Malignant pleural effusion\n  * Brain metastases or leptomeningeal disease\n  * Other sites not specifically noted must be reviewed and approved by the PIs\n  * Any site of disease that is not amenable to definitive local therapy\n* Unfit for best systemic therapy\n* Metachronous OMD\n* Secondary primary cancer, with the exclusion of basal cell carcinoma of the skin\n* Pregnant, lactating, or intending to become pregnant\n* Unwilling to provide informed consent",{"count":486,"type":20},"2 Years","The purpose of this registry study is to create a database-a collection of information-for better understanding standard treatments for esophageal and Gastroesophageal Junction Cancer\u002FGEJ cancer. Researchers will use the information from this database to learn more about the effectiveness of different treatment options.",[718,24],"Gastroesophageal-junction Cancer",[720,721],"Quality-of-Life Assessments","24-206","2026-05-19",{"date":724,"type":31},"2026-05-22",{"date":726,"type":31},"2024-08-12",{"date":728,"type":20},"2029-08-12",{"name":649,"class":38},""]